P2D Bioscience Awarded NIH Grant to Develop PD2007

P2D Bioscience has received a $1.5 million grant from the National Institutes of Health (NIH) to develop its lead dopamine transport inhibitor, PD2007, through IND safety and toxicology studies for future use in humans. More than a decade of preclinical testing and numerous scientific publications indicate PD2007’s efficacy at inhibiting dopamine transport in multiple brain regions.

Click here to read the entire release.

About The Author

Kevin Wilson

Other posts by

Author his web site


06 2011

Comments are closed.